HIG Capital completed its $250m acquisition of BioVectra, a contract drug manufacturer, from Mallinckrodt, a global biopharmaceutical company. "We are excited to support BioVectra's exceptional leadership and highly dedicated employees. BioVectra demonstrates a tremendous ability to generate robust organic growth and utilizes a broad set of technical capabilities to deliver outstanding service and quality. They are completing major capital expenditure programs to significantly expand capacity and the company is well positioned to capitalize on growing demand for their services," Mike Gallagher, HIG Capital Managing Director.